Viral Vector Manufacturing Market Projected to Reach USD 12.84 Billion by 2036: Driven by Gene Therapy Advances and CDMO Role

OpenPR Global

Overview

This article provides an overview of a market research report distributed by OpenPR. The report forecasts that the global viral vector manufacturing market will reach USD 12.84 billion by 2036, driven by the increasing number of approved gene therapies and growing investments in advanced biopharmaceuticals. Viral vectors are crucial for gene and cell therapies, and their complex manufacturing processes, requiring specialized facilities and strict GMP, lead many companies to outsource to expert CDMOs. A key technological trend highlighted is the shift from adherent to scalable suspension cell-based manufacturing platforms.

In Depth

This article serves as an overview of a market research report distributed by OpenPR.

Report Overview

This market research report analyzes the rapid growth of the global viral vector manufacturing market, driven by the increasing development and approval of gene therapies and expanding investments in advanced biopharmaceuticals. The market under investigation focuses on viral vectors, including adeno-associated virus (AAV), lentivirus, and adenovirus, covering application areas such as gene therapy, CAR-T cell therapy, and regenerative medicine. The geographical scope encompasses the global market, including trends in key regions like Europe, the UK, Germany, and Switzerland.

Key Findings / Results

The report projects that the global viral vector manufacturing market will reach USD 12.84 billion by 2036. This growth is attributed to the increasing recognition of viral vectors as essential components for gene and cell therapies, alongside the inherent complexity of their manufacturing processes. Viral vector production is highly intricate, demanding specialized facilities, stringent quality control, and strict adherence to Good Manufacturing Practice (GMP) standards. As most biotechnology companies lack the necessary in-house infrastructure for this, there is a growing trend to outsource viral vector production to specialized Contract Development and Manufacturing Organizations (CDMOs), citing high capital expenditure and specialized expertise as primary reasons. A significant technological development noted is the ongoing shift from traditional adherent cell culture systems to more scalable suspension cell-based manufacturing platforms, which improves production scalability and efficiency.

About the Publishing Entity

While the specific research firm authoring this report is not explicitly named, OpenPR is a press release distribution service, indicating that this information was likely provided by an unnamed research company. It can be inferred that the research firm possesses expertise in providing detailed analysis and insights into the pharmaceutical manufacturing, biotechnology, and advanced therapeutics markets, focusing on industry trends and market forecasts.